Determination of the global ER binding profiles by ChIP-seq analysis of breast tumors has shown that there is a high level of plasticity in ER binding in breast cancer (Ross-Innes et al., 2012), such that investigation of any association between A3B/ER binding regions and somatic mutations may entail whole-genome sequencing, coupled with ER and A3B ChIP-seq in the same tumor. The gene discussed is ESR1; the disease is neoplasm.